
The public body responsible for providing guidance and advice for England and Wales, the National Institute for Health and Care Excellence (NICE), is now clarifying an earlier statement, which suggested it did not recommend Leo Pharma’s atopic eczema treatment Adtralza (tralokinumab).
”It has come to our attention that the note to media issues on 8 April 2022 in relation to this appraisal may have created the inaccurate impression that final guidance had been issues by NICE,” the authority writes in a statement, emphasizing that Leo Pharma has been able to comment on the indicative rejection until May 4.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app